Somewhat Positive News Coverage Somewhat Unlikely to Impact Cerner (CERN) Stock Price
Headlines about Cerner (NASDAQ:CERN) have been trending somewhat positive on Tuesday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cerner earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.4869224747432 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment’s rankings:
- 5 must-read articles for healthcare leaders this week (beckershospitalreview.com)
- Readers Write: Report from AWS Re:Invent (histalk2.com)
- ETFs with exposure to Cerner Corp. : December 4, 2017 (finance.yahoo.com)
- Cerner Co. (CERN) Given Average Rating of “Hold” by Brokerages (americanbankingnews.com)
- Insider selling: Interim CEO unloads $35M in Cerner stock (beckershospitalreview.com)
Cerner (CERN) traded up $0.30 during trading on Tuesday, reaching $70.09. 1,657,530 shares of the company traded hands, compared to its average volume of 2,380,128. Cerner has a 12-month low of $47.01 and a 12-month high of $73.86. The stock has a market cap of $23,325.55, a P/E ratio of 31.05, a price-to-earnings-growth ratio of 2.26 and a beta of 0.94. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.77 and a quick ratio of 2.75.
A number of brokerages have weighed in on CERN. Morgan Stanley upgraded shares of Cerner from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $59.00 to $62.00 in a report on Thursday, August 10th. Jefferies Group set a $79.00 target price on shares of Cerner and gave the company a “buy” rating in a research note on Friday, October 13th. SunTrust Banks reissued a “buy” rating and issued a $75.00 target price on shares of Cerner in a research note on Monday, October 30th. Royal Bank Of Canada began coverage on shares of Cerner in a research note on Tuesday, September 19th. They issued a “top pick” rating and a $84.00 target price on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 target price on shares of Cerner in a research note on Wednesday, November 29th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $69.50.
In related news, COO Michael Nill sold 99,470 shares of Cerner stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $70.45, for a total transaction of $7,007,661.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Clifford W. Illig sold 4,000 shares of Cerner stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $65.96, for a total transaction of $263,840.00. Following the sale, the chairman now directly owns 1,229,719 shares in the company, valued at approximately $81,112,265.24. The disclosure for this sale can be found here. Insiders have sold a total of 833,470 shares of company stock worth $55,418,902 in the last ninety days. 13.11% of the stock is currently owned by insiders.
Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT). The Company offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations of all sizes. The Company’s segments include Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States.
Receive News & Stock Ratings for Cerner Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner Co. and related stocks with our FREE daily email newsletter.